Post-Pandemic Healthcare Could Feature More Biotech M&A

Experienced investors know that talk of mergers and acquisitions activity is a near constant in the healthcare industry. Due to the sluggish pace of deal-making last year owing to the onset of the coronavirus pandemic, as well as a bright post-pandemic outlook for some pharmaceuticals companies,...
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.